Abcam, ab251438, Anti-IDI1+IDI2 antibody [EPR17213] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal IDI1 antibody. Carrier free. Suitable for WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR17213,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab251438 is the carrier-free version of
ab205617
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
IDI1 (isopentenyl-diphosphate delta isomerase 1) and IDI2 (isopentenyl-diphosphate delta isomerase 2) are enzymes that catalyze the isomerization of isopentenyl diphosphate (IPP) to dimethylallyl diphosphate (DMAPP) an important step in the isoprenoid biosynthesis pathway. IDI1 is sometimes referred to as IPP isomerase. The molecular weight of IDI1 is approximately 33 kDa whereas IDI2 has a similar size. IDI1 is expressed in a wide range of tissues including the liver and heart. In contrast IDI2 has a more limited expression primarily found in skeletal muscle and testis.
Biological function summary
IDI1 and IDI2 are involved in the production of isoprenoids a diverse group of compounds that include cholesterol coenzyme Q and various hormones. These enzymes do not operate as part of a larger complex but instead function independently to facilitate the interconversion between IPP and DMAPP. The production of these molecules is essential for many physiological processes including cell membrane maintenance and hormone regulation.
Pathways
IDI1 and IDI2 play an integral role in the mevalonate pathway which is important for cholesterol biosynthesis and protein prenylation. In this pathway these enzymes help in providing substrates for key steps in the creation of cholesterol and other sterol molecules. IDI1 works closely with other enzymes like HMG-CoA reductase and squalene synthase which are key regulators within this same pathway.
IDI1 and IDI2 have connections to hypercholesterolemia and cardiovascular disease due to their roles in cholesterol biosynthesis. Altered activity or expression of these enzymes may lead to imbalances in cholesterol levels contributing to plaque formation in blood vessels. Therapeutic targeting of related enzymes like HMG-CoA reductase is already a strategy in managing these conditions highlighting the relevance of the isoprenoid pathway in disease pathology.